Parcc’s News
Categories
Research Teams
Decoding Chromatin Landscape to Elucidate Heart Regeneration
Team Leader: Ivana Zlatanova
Genetic Mechanisms of Aldosterone-Related Disorders
Team Leader: Maria-Christina Zennaro
In vivo imaging research
Team Leaders: Fabien Hyafil, Bertrand Tavitian
Paris Transplant Group (PITOR)
Team Leader: Alexandre Loupy
Immunotherapy and anti-angiogenic therapy in oncology
Team Leaders: Eric Tartour, Magali Terme-Zydel
Kidney, Vessels, Inflammation and Metabolism – KVIM
Team Leaders: Pierre-Louis Tharaux, Olivia Lenoir
Endotheliopathy and hemostasis disorders
Team Leader: David Smadja
Integrative physiopathology and therapy of cardiac diseases
Team Leaders: Jean-Sébastien Silvestre, Jean-Sébastien Hulot
Immuno-metabolic mechanisms of cardiovascular diseases
Team Leaders: Hafid Ait-Oufella, Ziad Mallat
Integrative Epidemiology of Cardiovascular diseases
Team Leaders: Jean-Philippe Empana, Xavier Jouven
Arterial Health and Disease in Women
Team Leader: Nabila Bouatia-Naji
Multi-organ dysfunction and cardiovascular pathology in metabolic diseases
Team Leader: Clément Cochain
Vascular Development and Disease
Team Leaders: Anne Eichmann, Eric Camerer
Research Highlights
Recent discoveries from PARCC teams

Atenolol or Bisoprolol after Myocardial Infarction without Recorded Heart Failure
Using French national health data on 11,558 patients treated in the Paris area after a myocardial infarction and with no sign of heart failure, the team compared the two most prescribed beta-blockers. Starting atenolol was associated with fewer major cardiovascular events at two years than bisoprolol, without a significant difference in overall mortality.
Subgroup analysis from Laurenceau et al., NEJM Evidence 2026 — © Massachusetts Medical Society.
Read the article →
Multimodal data-driven clustering identifies two distinct patterns of heart failure with preserved ejection fraction
In the PACIFIC-Preserved cohort, combining clinical data, cardiac imaging and high-throughput plasma proteomics with machine learning split patients with HFpEF into two biologically distinct groups. The inflammatory group, marked by cardio-skeletal injury and renal dysfunction, carried a higher risk of adverse outcomes in an external validation cohort.
Fig. 1 from Hulot et al., Nat Commun 2026 — CC BY-NC-ND 4.0.
Read the article →
Blood-borne sphingosine 1-phosphate maintains vascular resistance, blood pressure, and cardiac function in mice
Sphingosine 1-phosphate (S1P), a lipid released by red blood cells, circulates bound to HDL or albumin. Mice lacking all circulating S1P had low blood pressure and weaker heart contraction, both corrected by transfusing S1P-producing red cells. Albumin-bound S1P increased vascular resistance through the S1PR3 and S1PR2 receptors.
Fig. 1 from Del Gaudio et al., PNAS 2026 — CC BY-NC-ND 4.0.
Read the article →Parcc Communities
Follow us on LinkedIn
So you don't miss any of our news.